This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Earnings Estimates Rising for Patterson Cos. (PDCO): Will It Gain?
by Zacks Equity Research
Patterson Cos. (PDCO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Patterson Companies (PDCO) Catches Eye: Stock Jumps 5.9%
by Zacks Equity Research
Patterson Companies (PDCO) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Patterson Companies (PDCO) Q3 Earnings Top Estimates, Up Y/Y
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal third-quarter results benefit from higher revenues and solid show by Dental as well as Animal Health segments.
Patterson Cos. (PDCO) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Patterson Cos. (PDCO) delivered earnings and revenue surprises of 27.03% and 2.75%, respectively, for the quarter ended January 2020. Do the numbers hold clues to what lies ahead for the stock?
STERIS' (STE) Growth Picture Impressive Amid Rising Costs
by Zacks Equity Research
STERIS (STE) growing steadily on favorable underlying market trends, along with new product and service offerings.
What's in Store for Patterson Companies' (PDCO) Q3 Earnings?
by Zacks Equity Research
Patterson Companies (PDCO) expects Animal Health sales to have been soft in fiscal Q3.
Abbott's Alliance With Insulet to Fortify Diabetic Care Unit
by Zacks Equity Research
Both Abbott (ABT) and Insulet will use a pay-as-you-go model to enhance customer acceptance.
Integra LifeSciences Grows Organically Amid Supply Issues
by Zacks Equity Research
Integra LifeSciences' (IART) Codman Specialty Surgical segment registers impressive organic growth in Q4.
Integer Holdings Acquires Inomec, Extends Global Foothold
by Zacks Equity Research
Integer Holdings' (ITGR) Inomec buyout is likely to boost R&D pipeline and also strengthen and expand global foothold.
HealthEquity (HQY) Stock Up on Solid Fiscal 2020 Results
by Zacks Equity Research
HealthEquity (HQY) raises fiscal 2020 view for top and bottom line.
Baxter's Latest Acquisition to Boost Advanced Surgery Arm
by Zacks Equity Research
Baxter's (BAX) Advanced Surgery arm boasts of a wide spectrum of products.
Here's Why You Should Hold on to Cerner (CERN) Stock Now
by Zacks Equity Research
Cerner (CERN) is gaining traction from prudent strategic deals and big data based EHR system. However, weak margins remain a woe.
Here's Why You Should Invest in Cardinal Health Stock Now
by Zacks Equity Research
Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment.
Here's Why You Should Add DaVita (DVA) to Your Portfolio Now
by Zacks Equity Research
DaVita (DVA) gains from solid results in the fourth quarter of 2019.
Bleak Outlook for Medical Dental Supplies Industry
by Sreyoshi Mukherjee
Despite digital dentistry and AI being dominant market trends, near-term prospects of the Dental industry look dull.
PDCO vs. WST: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PDCO vs. WST: Which Stock Is the Better Value Option?
Has Patterson Companies (PDCO) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (PDCO) Outperforming Other Medical Stocks This Year?
Can Value Investors Consider Patterson Companies (PDCO)?
by Zacks Equity Research
Patterson Companies (PDCO) stock may be a good choice for value-oriented investors right now from multiple angles.
Moving Average Crossover Alert: Patterson Companies
by Zacks Equity Research
Patterson Companies, Inc. (PDCO) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Dentsply (XRAY) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Dentsply (XRAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Masimo Posts Solid Preliminary 2019 Results, Issues Guidance
by Zacks Equity Research
Higher revenues and upbeat 2020 outlook benefit Masimo's (MASI) preliminary full-year 2019 results.
Should Value Investors Buy Patterson Cos. (PDCO) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Baxter Posts Upbeat Q4 Preliminary Results, Issues Guidance
by Zacks Equity Research
Higher revenues, growth in all geographic segments and six business units benefit Baxter's (BAX) Q4 preliminary operating results.
Here's Why You Should Hold on to Cardinal Health Stock Now
by Zacks Equity Research
Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment. However, integration risks remain a concern.
PDCO or WST: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PDCO vs. WST: Which Stock Is the Better Value Option?